Vantage Wealth’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q4
Sell
-128,950
Closed -$6.93M 29
2014
Q3
$6.93M Buy
128,950
+1,775
+1% +$94K 4.44% 5
2014
Q2
$6.71M Sell
127,175
-9,150
-7% -$468K 4.46% 3
2014
Q1
$7.2M Buy
136,325
+3,700
+3% +$171K 4.6% 3
2013
Q4
$5.32M Buy
132,625
+2,500
+2% +$98.4K 3.44% 20
2013
Q3
$4.92M Sell
130,125
-1,425
-1% -$55.6K 3.87% 16
2013
Q2
$5.16M Buy
+131,550
New +$5.12M 4.1% 11

Other funds holding TEVA

Vantage Wealth's TEVA Position: Q4 2014 in Review

Vantage Wealth sold out of Teva Pharmaceuticals (TEVA) in Q4 2014, closing a stake of 128,950 shares — an estimated $6.93M sold.

Vantage Wealth first reported a position in TEVA in Q2 2013 and held it in 6 quarters. The position peaked at $7.2M in Q1 2014. 821 funds tracked by Wall St. Rank hold TEVA as of Q4 2014.

  • Vantage Wealth reported no remaining Teva Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Vantage Wealth sold 128,950 Teva Pharmaceuticals shares in Q4 2014, an estimated $6.93M.
  • Vantage Wealth first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 6 quarters.
  • Vantage Wealth's Teva Pharmaceuticals position peaked at $7.2M in Q1 2014.
  • 821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2014.

Based on Vantage Wealth's 13F filing for Q4 2014, filed 6 Feb 2015.